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Available online 19 August 2012Abstract No systemic therapy is effective against pancreatic cancer (PC). Pancreatic cancer stem cells (PCSC) are hypothesized to
account for therapeutic resistance. Several PCSC subpopulations were reported, each characterized by different markers. To be able
to target PCSC, we sought to better define this putative heterogeneity. Therefore, we tested most of the known putative PCSC
markers in established and fresh tumor cell lines. CD20, CD24, CD44, CD133, CD184 (CXCR4), CD326 (EpCam, ESA), Sox-2, OCT 3/4,
and the side-population (SP) were tested in five PC cell lines, and the effects of confluency, hypoxia, radiation, and gemcitabine on
the SP. The testing phase suggested several putative PCSC populations thatwere further tested and validated for their tumor-initiating
capacity against known PCSC in 3 established and 1 fresh PC cell lines. Cell surface and intracellular markers showed significant
variability among cell lines. SP was the only common marker in all cell lines and consistently less than 1%. SP response to confluence,
hypoxia, radiation, and gemcitabine was inconsistent between cell lines. The initial testing phase suggested that SP/CD44-CD24-
CD326+ cells might be a novel PCSC subpopulation. Tumor initiation capacity tests in nude mice confirmed their increased
tumorigenicity over previously reported PCSC. Our data better define the heterogeneity of reported PCSC in cell lines tested in this
study.We propose that prior to targeting PC via PCSC, onewill need to gainmore insight into this heterogeneity. Finally, we show that
SP/CD44-CD24-CD326+ cells are a novel subpopulation of pancreatic cancer tumor initiating cells. Further mechanistic studies may
lead to better targeting of PC via targeting this novel PCSC.
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Pancreatic cancer is the fourth-leading cause of cancer
deaths in both men and women in the United States. While
the average cancer patient can expect a 69% 5-year
survival, a patient with pancreatic cancer has a dismal 5%
5-year survival (Horner et al., 2009). Despite advances in
other cancer treatments, pancreatic cancer survival has
not significantly improved over the last several decades. As
a result, new pancreatic cancer therapies could be of
significant value. One such therapy could target pancreatic
cancer stem cells (PCSC).
The cancer stem cell hypothesis suggests that current forms
of chemotherapy and radiation may not target cancer stem
cells, thus allowing for recurrence (Reya et al., 2001). Cancer
stem cells, originally described in leukemia (Bonnet and Dick,
1997), have recently been evaluated in many solid organ
cancers (Rosen and Jordan, 2009; Visvader and Lindeman,
2008). One of several problems with the cancer stem cells
hypothesis is the significant heterogeneity reported among
cancer stem cells; different markers are reported to identify
cancer stem cells in the same histology. In pancreatic cancer
alone, CD24, CD44, ESA (Epithelial surface antigen), CD133,
CXCR4, and the side population (SP) have all been reported by
different laboratories to designate populations of PCSC
(Hermann et al., 2007; Li et al., 2007; Sergeant et al., 2009).
In particular, one seminal study has suggested that CD44+/
CD24+/ESA+cells have a 100-fold increased tumorigenic poten-
tial (Li et al., 2007). Additionally, other groups have indepen-
dently suggested CD44+/CD24- and CD44+/CD133+ as possible
tumor-initiating cells in 4 established pancreatic cancer cell
lines (Kallifatidis et al., 2009). Although not necessarily
mutually exclusive, these studies lead us to question the
identity of an optimal PCSC in terms of potential therapeutic
targeting. The ideal PCSC should be found in asmany pancreatic
cancer cell lines and fresh tumors should as possible.
Tumorigenic potential and resistance to therapy has been
evaluated by growth in immunosuppressed mice as well as
resistance to therapy assays (Reya et al., 2001). The SP and
CD44+CD24-cells in pancreatic cancer have been reported to
be resistant to gemcitabine, the standard chemotherapy agent
for pancreatic cancer (Kallifatidis et al., 2009; Zhou et al.,
2008). Yet, other laboratories suggested that cancer stem cells
are radiation and hypoxia resistant (Tavaluc et al., 2007; Vlashi
et al., 2009).We reasoned that to effectively target pancreatic
cancer via targeting cancer stem cells, it is necessary to
identify an optimal population of cancer stem cells that can be
found in all or the majority of pancreatic cells tested and that
possess greater tumor-initiating capacity. Therefore, we
designed the present study to comprehensively investigate
previously reported populations of PCSC, within one laboratory
and in common pancreatic cancer cell lines and fresh tumors.
Several pancreatic cancer cell lines and human tissue
samples were surveyed for cell surface, intracellular, and
functional markers. CD20, CD24, CD44, CD133, CD184 (CXCR4),
CD326 (EpCam), Sox-2, and OCT3/4 were examined in
established pancreatic cancer cell lines. The functional marker,
i.e., SP, was also determined in these cell lines. Side population
was a term originally used to define a group of hematopeotic
stem cells that had the ability to efflux the fluorescent vital dye
Hoechst 33342 (Goodell et al., 1996). These cells have been
shown to be long-term repopulating cells found in both normaltissues and cancer cells. However, when compare to non-SP,
the SP has higher expression of genes linked to regulation of
stem cell function and has been described in a variety of cancers
(Wu and Alman, 2008). Since previous reports also suggest that
the SP is influenced by cell culture density, we examined SP
under 2 different density conditions (Tavaluc et al., 2007). The
cardinal aimwas to define amarker or a combination ofmarkers
that were common to all cancers tested, and to test its
therapeutic resistance and tumor-initiating capacity. Various
logistic combinations of surfacemarkers and SPwere examined;
the combination of SP plus surface markers was found to be a
potentially better indicator for PCSC in terms of tumor-
initiating capacity. Using these techniques, we prospectively
identified a population of novel PCSC in the testing phase.
In the validating phase, these cells were subjected to a
xenotransplantation assay and found to have superior
tumorigenicity compared to controls. Our findings poten-
tially indicate that PCSC are a very heterogeneous
population of cells in terms of markers, the response to
chemotherapy, radiation, and hypoxia. Importantly, we
show a novel class of putative PCSC or pancreatic cancer
cells with greater tumor-initiating capacity that has not
previously been described.
Results
Expression of individual cell surface and intracellular
markers is heterogeneous among various pancreatic
cancer cells
CD20, CD24, CD44, CD184, CD326, CD133, Sox-2, and OCT 3/4
were examined by flow cytometry in 5 pancreatic cancer cell
lines (Fig. 1A, B). CD20 is expressed by less than 0.5% of the
cells in four cell lines, and by 35% of BxPC-3 cells. CD24 is
expressed by 12.4–99.6% of cells. CD44 is expressed by 75% of
cells in all cell lines tested. CD184 is expressed by 0.21% of
Su86.86 cells and is virtually undetectable in other cell lines.
CD326 is ubiquitous in greater than 93% of cells in all cell lines
tested. CD133 is only detectable in Su86.86 and Capan-1,
comprising 63–69% of total cells. Interestingly, Su86.86 and
Capan-1 are the only cell lines derived from pancreatic cancer
liver metastasis, suggesting a potential role of CD133 in
metastases. Intracellular markers, Sox-2 and OCT 3/4 are
present in 5–90% and 0.2–57% of total cells, respectively.
The premise of this study was that in order to target PC
that is derived from a very heterogenic population of
patients via targeting PCSC, one would need to identify a
population of putative PCSC that exists in as many
pancreatic cancer cells as possible. CD184 and CD133 are
not expressed by all pancreatic cell lines and thus,
individually, would not be good candidate markers in PC
cells tested. Based on other biological systems generated
from stem cells excluding embryological systems, stem cells
comprise a rare population of cells. CD24, CD44, CD136,
Sox2, and OCT3/4 are expressed byN50% of the PC cells and
as such are unlikely to be individually good candidates to
designate PCSC markers. None of these markers appear to be
present at a consistent level throughout all cell lines tested.
This wide range of expression of both extracellular and
intracellular markers suggests that no individual marker
alone is sufficient to identify a putative cancer stem cell.
Figure 1 Cancer stem cells markers expression. Comparative expression of extracellular (A) and intracellular (B) cancer stem cells
markers in 5 pancreatic cancer cell lines.
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In panc-1, SW1990, Su86.86, BxPC-3, and Capan-1, the SP
comprises less than 1% of total cells when defined by the
inhibitor verapamil (Fig. 2). The SP was examined in cells that
were 1 day beyond complete confluency (super-confluent) and
in cells that were approximately 70–80% confluent (sub-
confluent). Previous studies had suggested that lower con-
fluency increases the SP (Tavaluc et al., 2007). However, our
results cannot confirm those findings. In contrast, our results
show that there is no statistical difference in the SP detected
under super-confluent or sub-confluent conditions. Given
these findings, for subsequent SP studies, we elected to use
sub-confluent cell culture conditions. Based on the fact that
the SP is consistently rare and exists in all cell lines, it appears
to be a better candidate for a ubiquitous marker of PCSC than
the individual cell surface markers tested. Based on these
findings and on the fact that the SP is a functional marker,
we reasoned that the SP could potentially be a common
ubiquitous marker of PCSC, and that other previously
reported surface markers potentially better define various
subpopulations within the SP. Additionally, since the SP was
the only consistent marker, we further tested their
response to chemotherapy, radiation, and hypoxia.
Side population is not consistently affected by
exposure to gemcitabine
Gemcitabine is a commonly used chemotherapy in patients
with pancreatic cancers. Previous in vitro studies have
suggested that panc-1 cells exposed to 5 μg/ml gemcitabine
have a 10.7% increase in the SP (Zhou et al., 2008). Wehypothesized that gemcitabinewould increase the relative size
of the SP, suggesting that SP cells may be relatively resistant to
gemcitabine. Cells were exposed to clinically relevant increas-
ing doses of gemcitabine: 0.02 μg/ml, 0.01 mg/ml, and
1 mg/ml. The clinically relevant dose is approximately
0.01 mg/ml since clinical peak serum concentration is
0.01 mg/ml to 0.04 mg/ml (Noble and Goa, 1997). Cells were
exposed for 48 hours or 1 cell cycle. Our results demonstrate no
statistically significant change in the SP with gemcitabine
exposure (Fig. 3A). Given these findings, we concluded that the
SP might not be affected by chemotherapy in terms of relative
proportion in all pancreatic cancer cells tested with the
exception of BxPC-3 (0.01bpb0.05). To further test the SP as
a putative pancreatic cancer stem cell, we next examined its
response to hypoxia.
Side population increases with hypoxic exposure
Tumors, as they enlarge, tend to have some degree of hypoxia,
particularly at central portions of the tumor. In neuroblastoma,
hypoxia increases the SP and results in a highly invasive
migratory group of cells that show increased tumorigenicity
(Das et al., 2008). In colon cancer, a 3.2-fold increase in SP was
found with exposure to 0.5% oxygen (Tavaluc et al., 2007).
However, there are no studies that have reported the effect of
hypoxia on SP in pancreatic cancer. We exposed cells to 1%
oxygen, 5% carbon dioxide, and 94% nitrogen. Our results show
that in 3 of 4 cell lines tested, hypoxia increases the SP
(Fig. 3B). Panc-1 and Su86.86 show a statistically significant
increase of about 2.5-fold with hypoxia. SW1990 cells have a
4-fold increase in the SP with hypoxia with a statistical trend
(p=0.015 adjusted to multiple comparisons). Our results
Figure 2 Side population. The side population is rare and exists in all pancreatic cancer cell lines tested. Comparisons between
cells grown under super-confluent and sub-confluent conditions show no statistical difference in the side population for any of the
cell lines, with pN0.05 in all cases and using a 2-sided t-test.
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gemcitabine, it may well be resistant to hypoxia.Side population is not consistently affected by
radiation exposure
Radiation is often used to treat the local tumor bed after
surgery or to decrease the size of locally advanced tumors
before surgery. However many tumors re-grow in the
irradiated field, suggesting the possible radiation resistance
of PCSC. Radiation resistance of the SP has been suggested
in studies of bladder cancer and breast cancer cell lines (Han
and Crowe, 2009; Ning et al., 2009). However, there are no
studies of the SP and radiation in pancreatic cancer. After
exposure to 4 Gy radiation, pancreatic cell lines appear to
have variable responses to radiation (Fig. 3C). Our results
demonstrate that 2 of 4 cell lines show an increase in SP,
while other cell lines show a decrease. However, none of the
comparisons are statistically significant.
Overall, our survey of pancreatic cancer SP response
to therapy shows significant variability and inconsistency.
Evaluation of 4 pancreatic cancer cell lines shows that the SP is
not gemcitabine resistant in 3 out of 4 cell lines, or radiation
resistant in 2 out of 4 cell lines. In contrast, hypoxia appears to
increase the SP in the majority of cell lines tested. This
variability in response suggests that the SP alone may not be
an adequate cancer stem cell marker.Various combinations of side population and cell
surface markers may identify a better population of
pancreatic cancer stem cells
Since neither surface markers nor the functional marker
of SP alone appear to be optimal cancer stem cell markers,we subsequently examined them in combinations. Previous
studies in pancreatic cancer have shown the CD44+ CD24+ CD
326+ cells have 100-fold increased tumorigenicity (Li et al.,
2007). Additionally, a recent study examined the surface
markers within the SP of a single cell line, SW 1990. This
study suggests that SP cells have more CD44+CD24+ cells
than NSP cells (Yao et al., 2010). Therefore, we hypothe-
sized that a surface marker combination that is present in
relatively higher quantities in the SP compared to the non-SP
could be a better marker combination for a putative cancer
stem cell. Our in vitro studies of SP and CD44, CD 24, CD 326
demonstrated significant variability between cell lines
(Fig. 4A–E). Focusing on combinations that are statistically
significantly higher in the SP than the NSP, we discovered a
pattern between cell lines (Fig. 4G). CD44-CD24-CD326+
cells are higher in the SP than NSP in 4 out of 5 cell lines. No
other combinations are consistently higher in the SP than
NSP. When comparing this combination to the previously
described CD44+CD24+CD236+ cells, our results show that
these “triple positive” cells are lower in the SP than in the
NSP in all cell lines (Fig. 4F). Given these in vitro results, we
further hypothesized that SP/CD44-CD24-CD326+ may be
better candidates for a putative cancer stem cells than the
triple positive cells. We further tested this hypothesis with
xenotransplantation.
Xenotransplantation demonstrates that CD44-CD24-
CD326+ has greater tumor initiating capacity
Since transplantation of all combinations and permutations
of CD44, CD24, CD326, NSP, and SP is costly prohibitive
(testing 5 markers will require 5! permutaional combina-
tions, i.e., 250 different combinations). Thus, we selected 9
groups of particular interest and appropriate controls. Based
on the surface marker distribution reported above (Fig. 4G),
Figure 3 Side population response to chemotherapy, hypoxia,
and radiation. (A) Cells were exposed to clinically relevant
increasing doses of gemcitabine: 0.2 μg/ml; 0.01 mg/ml; and
1 mg/ml. There is no statistical significance in the relative
proportion of the SP in 4 of 5 cell lines tested. Only in BxPC-3 does
there appear to be a statistical trend (+, 0.01bpb0.05, adjusted to
multiple comparisons) where 0.01 mg/ml and 1 mg/ml may
increase the relative proportion of the side population relative to
control cell. (Significance evaluated by Dunnett's test, n=3).
(B) Cells exposed to 1% oxygen were compared with cells under
normal culture conditions in terms of side population. There is a
statistically significant increase in side population under hypoxic
conditions in panc-1 and Su86.86 cells. (*, p=0.009 and p=0.004,
respectively). In SW1990 cells, there is a statistical trend
(+, p=0.015) toward increased side population with hypoxic
exposure (adjusted to multiple comparisons). Significance was
evaluated by a 2-sample t-test. (C) Cells exposed to 4 Gy radiation
were compared with cells under normal culture conditions.
Although in 2 of 4 cell lines tested the SP increased after radiation,
there is no statistically significant difference between radiated cells
and control cells. Significance was evaluated by a 2-sample t-test.
Results are an average of 3 repetitions.
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SW1990; we transplanted the following groups: whole cell
line; SP; NSP; CD44+CD24+CD326+; CD44-CD24-CD326+; SP/
CD44+CD 24+CD326+; NSP/CD44+CD24+CD326+; SP/CD44-
CD24-CD326+; and NSP/CD44-CD24-CD326+. We transplanted
these 9 different groups, each with 100 cells per injection,
into aythmic nude mice. Two front limb flank injections were
used per animal, and 13 animals per group, resulting in 26
injections per group. We chose this number of animals based
on prospective statistical analysis to have an 80% power to
detect a difference between groups in which groups with
tumor development were estimated to have 62% of animals
with tumor. Analysis was done with a 2-tailed Fisher's exact
test with significance determined by a very strict pb0.005
because of proper adjustment for multiple comparisons.
Statistical evaluation showed that the presence of tumor on
one flank of a single animal did not influence the growth of a
second tumor on the adjacent flank of the same animal.
Therefore, we counted each injection as a separate and
independent event, giving a total of 26 evaluable sites for
each group tested. Actual FACS sort data are shown in
Supplementary Fig. S1. Tumor growth results demonstrate
that the SP/CD44-CD 24-CD326+ cells grew in 12 of 26 sites,
which is the only group that is statistically significantly
different than control that is sorted whole cells (Fig. 5A). Of
note, the CD44+CD24+CD326+ cells had the second-largest
number of tumors, 8 of 26; however, this was not statistically
different than control. These results suggest SP/CD44-CD 24-
CD326+ are more tumorigenic than controls. Interestingly,
whole cells grew in 2 of 26 injections. The reasons for this are
unclear; it is the first reported tumor growth of a whole cell
line, when only 100 cells have been injected.
Several comparisons were made between the groups
using Kaplan–Meier analysis to test whether the time to
development of first tumors was different between the
various groups (Fig. 5B–D). In comparing the contribution
of SP to surface markers, Fig. 5B demonstrates that the
SP enhances tumorigenicity of CD44-CD 24-CD326+ cells
(p=0.0003). However, SP does not appear to change the
tumorigenicity of CD44+CD24+CD326+ cells (Fig. 5C).
Interestingly, SP alone does not provide the same tumor-
igenicity, suggesting that SP alone or surface markers alone
have less tumorigenicity than the combination (Fig. 5D,
p=0.45). Comparing our putative cancer stem cell popula-
tion of SP/CD44-CD24-CD326 to the triple positive cells,
we find that the former has better tumor formation (12/26
versus 8/26), but the difference is not statistically signif-
icant based on the p-value set at 0.005 to adjust for
multiple comparisons. Similarly, the time to development
of first tumor between CD44+CD24+CD326+ and SP/CD44-
CD 24-CD326+ is not statistically significant (p=0.18).
To further verify these results, we conducted a validating
experiment. We examined these selected populations in
several additional cell lines. Xenotransplantation of 100 cells
of SP, CD44+CD24+CD326+, SP/ CD44-CD 24-CD326+, and
control cells was done using Su86.86 and Panc-1 cell lines. One
additional human fresh pancreatic ductal adenocarcinoma
cell line, designated human tumor K, was also tested. Fig. 6
shows the number of tumors that grew in these xenotrans-
plantation experiments. Up to 15 mice per group had 100 cells
of the sorted populations injected into their flanks bilaterally
(Fig. 6). When looking at each cell line, the comparisons to
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in any of the 3 sorted groups. Additionally, comparisons
between groups within a cell line show no difference (data not
shown). However, when the groups are pooled across the 3 cell
lines to approximate a population of various patients, the SP/
CD44-CD 24-CD326+ have absolute 20% higher growth ratethan the CD44+CD24+CD326+ cells (Fig. 6B, p=0.027).
Furthermore, examined in another way, the time to first
tumor development also shows advantage to the SP/ CD44-
CD24-CD326+ subpopulation. In each individual cell line, none
of the groups were statistically different from each other in
terms of which group developed tumors first (data not shown).
Figure 5 Tumor-initiating capacity testing experiment. Nine different subpopulation of cells derived from SW1990 cells were
xenotrasplanted. Each group was compared to a whole cell control with p-values listed. The side population CD44-CD 24-CD326+ (SP/–+) is
the only group that is statistically significantly more tumorigenic than controls (A). Further testing was done using Kaplan–Meier analysis to
test whether the time to development of first tumor was different between the various groups (B-E). In comparing the following couplets:
SP/–+vs –+; SP vs. NSP (p=0.45); SP/+++ vs. +++ (p=0.88); and SP/–+vs. +++ (p=0.18), only SP/–+vs. –+showed a statistically
significant difference (p=0.0003) (B).
Figure 4 Pancreatic cancer stem cells surface markers expression in the side population (SP) versus the non-side population (NSP).
CD44, CD24, CD326 positive and negative combinations are shown within the non-side population (NSP) and side population (SP) in
various cell lines. Here we show that various combinations are statistically significantly different from each other (*, pb0.01) in
different cell lines (A-E). Comparing the previously described CD44+CD24+CD326+ cells with CD44-CD24-CD326+ cells shows that the
latter is present in relatively higher amounts in the SP than in the NSP in 4 of 5 cell lines (F). The triple positive cells are lower in the
SP than NSP in all cell lines. Cell surface marker combinations that are statistically higher in the SP than in the NSP are shown: CD44+/
CD24-/CD 326+ is only significant in panc-1 cells; CD 44+CD24-CD326- and CD44-CD24+CD326+ are significant in 3 of 5 cell lines. CD
44-CD24-CD326+ is significant in 4 out of 5 cell lines(G).
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(Fig. 6C), the SP/CD44-CD 24-CD326+ developed tumors more
quickly than the CD44+CD24+CD326+ (p=0.037).Discussion
Despite significant research, the identity of pancreatic cancer
stem cells remains controversial (Hermann et al., 2009). While
different groups have identified CD44+CD24+CD326+ cells as
cancer stem cells, others suggest that CD44+CD 24- and CD
44+CD133+ are also cancer stem cells (Kallifatidis et al., 2009;
Li et al., 2007). Although the identity remains questionable,
detailed proteomic and therapeutic studies have already been
conducted on different putative cancer stem cells (Dai et al.,
2010; Mueller et al., 2009; Rausch et al., 2010). The value ofFigure 6 Tumor-initiating capacity validating experiemnt. Xenot
tumor K. Table A shows the number of tumors that grew per total n
cell control with p-values listed. Table B shows combined analysis po
between groups. Graph C shows the time to the development of a tu
developed tumors more quickly than the CD44+CD24+CD326+ (p=0these types of studieswould be improved if an agreement could
be established on the identity of pancreatic cancer stem cells.
This study was designed to examine previously described
cancer stem cell assays in pancreatic cancer. Specifically, we
examined surface markers, intracellular markers, SP, and
effects of radiation, hypoxia, and gemcitabine. In studying the
combinations of surface markers and SP, we have identified a
novel combination that may be more tumorigenic than
previously described CD44+CD24+CD326+ cells. By xenotrans-
plantation, we find that SP/CD44-CD24-CD326+ cells are
highly tumorigenic in pancreatic cancers.
In this study of PCSC, we prospectively defined the
characteristics of the population we thought would be the
best pancreatic cancer stem cells. Most researchers in this
field would agree that cancer stem cells are a small subset of
cancer cells that have the ability to self-renew and maintainransplantation using 100 cells in Su86.86, Panc-1, and Human
umber of sites injected. Each group was compared to the whole
oling numbers of tumors from all 3 cell lines and the comparisons
mor combining all 3 cell lines together. SP/CD44-CD 24-CD326+
.037).
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stem cells hypothesis, we searched for a rare population of
cells, since cancer stem cells are thought to be a very small
fraction of the bulk of the tumor. We also searched for a
population that would be present in the majority of cell
lines, i.e., consistency between cell lines. A putative cancer
stem cell would also likely be resistant to treatments such as
chemotherapy and radiation. Finally, a cancer stem cell also
must demonstrate self-renewal by growth in an immuno-
compromised mouse model.
Our survey of the effects of radiation, hypoxia, and
gemcitabine on the SP shows that there may not be a
consistent effect on this sub-population. This suggests that
the SP alone may not be the best method to isolate pancreatic
cancer stem cells. Other studies have found that CD24
and ALDH are enriched after gemcitabine exposure and are
strongly associated with subsequent tumor growth (Jimeno et
al., 2009). Although we did not examine the effects of therapy
on the SP/ CD44-CD24-CD326+ cells in this survey study, that
may be a worthy topic of future studies as we begin to
elucidate the mechanisms of increased tumorigenicity of
this population.
The combination in vitro results suggested that CD44-
CD24-CD326+ cells are present in greater quantities in the
SP, while CD 44+CD 24+CD326+ cells are higher in the NSP.
These results directly conflict with previous reports which
suggested that SP contains more CD44+CD24+ than NSP
(Yao et al., 2010). However, since our findings are present in
4 of 5 cell lines, compared to a single cell line in previous
studies, we believe that our results may be more relevant.
Of note, CD44-CD24-CD326+ cells were also detected in
fresh tumor cells (Fig. 6). Also, these same studies suggest
that the SW1990 cell line contains a significant amount of
CD133+ cells, particularly in SP cells. However, our results
suggest that only Su86.86 and Capan-1 cell lines have
significant amounts of CD133+ cells.
Xenotransplantation assays were performed in athymic
mice. However, xenotransplantation assay to examine stem
cell tumorigenicity has become more controversial. The exact
immunocompromised nature of the model may significantly
influence results. Commonly athymic or NOD/SCID mice are
used. However, in melanoma, 27% of unselected melanoma
single cells were reported to give rise to tumor in a model that
used highly immunocompromised NOD/SCID interleukin-2
receptor gamma chain null (Il2rg−/−) mice (Quintana et al.,
2008). These authors suggest that using NOD/SCID mice may
underestimate the population of possible cancer stem cells.
However, we speculate that perhaps using a highly immuno-
compromised mouse such as Il2rg−/− may overestimate
putative cancer stem cell. In all cancer studies, models such
as xenotransplantation are used to model the actual human
condition as closely as possible. Using a highly immunocom-
promised mouse is possibly further from the state of a human
being with cancer than using simply athymic mice. Tumors
that grow in less immunocompromised models may be a more
rigorous test of tumorigenicity. To address this controversy,
some experts have suggested the use of genetically engi-
neered mouse models that may allow examination of the
cancer stem cell hypothesis in more syngeneic, immunocom-
petent setting (Lonardo et al., 2010).
Additionally, the exactmethod of xenotransplantationmay
be important. As in previous studies, we used a 25% matrigelcell suspension for injection. Although commonly used in
maintenance of human embryonic stem cells, its variability
has led researchers to investigate alternatemethods (Nagaoka
et al., 2010). Several studies have suggested increased tumor
formation from tumor cell lines when injected in matrigel
(Kleinman and Martin, 2005). The properties of matrigel may
explain why 2 of 26 tumors grew in mice injected with 100
whole, unsorted cells. However, previous studies that identi-
fied CD44+CD24+CD326+ cells as cancer stem cells also used
matrigel (Li et al., 2007). Regardless, when compared to this
control group that grew 2 tumors, the SP/CD44-CD24-CD326+
cells showed statistically significant increased tumorigenicity
in SW1990. The previously described CD44+CD24+CD326+
cells did not show statistically significant increased tumorige-
nicity over control. One explanation for this finding is that the
previously described triple positive cells were studied exclu-
sively in fresh human pancreatic cancer tissues. The different
results between previously reported PCSC from fresh tumors
and our results may be another source of heterogeneity.
Additionally, the present study uses rigorous statistical
planning to pre-determine the number of animals needed to
show a difference in growth. Most studies use between 3 and
18 injections for analysis, while we have used between 16
and 30 for each group. While the increased tumorigenicity of
SP/CD44-CD24-CD326+ cells is most statistically significant in
our SW1990 results, it is also present in the pooled confirmatory
studies done in Su86.86, panc-1, and human tumor K. However,
it cannot be ignored that each individual cell line has variable
results. Individually, the increased tumorigenicity of SP/ CD44-
CD24-CD326+ is most apparent for SW1990 and Su86.86 cells;
for panc-1 and human tumor K, this increased tumorigenicity
seems to be abrogated. One technical explanation for this could
be poor FACS sorting, which could also possibly explain the
growth of numerous (16 of 30) tumors in the whole-cell
population of panc-1 cells. Another possibility is that different
cell lines may have different tumor-initiating cells. Based on
other biological systems where stem cells were described, stem
cell markers were not expressed by the majority of the cells
within a system. Any stem-cell marker should be rare enough to
denote a unique population of cells with stem cells properties.
The only biological system where stem cell markers are
expressed by the majority of cells is in embryonic systems.
However, it is possible that in cancer, this rule does not apply.
Moreover, in this study, using the cell lines we used, and the
fresh tumor we used, PCSC seem to be heterogeneous.
Potentially, these findings should make future studies aware
of heterogeneity and should be explored and reported as such in
future studies on the subject.
In terms of PCSC function, and based on this study alone,
we can discuss only one functional aspect of PCSC: Tumor
initiating capacity. Cancer stem cells are hypothesized to
have play roles in asymmetric division, metastasis, and
resistance to therapeutic agents. However, the current
manuscript only examines the methods by which we can
identify the putative PCSC. The SP+/CD44-CD24-CD326+
cells were found to be more tumorigenic, suggesting that
they may play a role in tumor initiation and propagation.
There can be several sources of functional heterogeneity in
PCSC. Different origins i.e. established cell lines vs. fresh
surgical specimen, and cell lines originated from primary
tumors vs. metastases can potentially results in different
ability to generate tumors ro other functions. We propose
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it by these four parameters for better accuracy. Although
we examined the ability of some PCSC to resist radiation,
chemotherapy and hypoxia in this study, we have not examined
the exact role these cells might play in metastasis or direct
resistance to chemotherapy. Clearly, not all subpopulations of
putative PCSC have similar ability to negotiate chemotherapy,
radiation or hypoxia and thus might not be ideal tools to
identify putative PCSC.
In summary, the present study offers an extensive survey of
pancreatic cancer stem cells. It challenges previous studies that
suggest that surfacemarkers or SP alone are sufficient to define
the cancer stem cell compartment. Instead, we find that the
combination of these markers may be better putative cancer
stem cells than either population alone.
Materials and methods
Cell culture
All cells were maintained in 5%CO2, 37.5 °C incubators.
Panc-1, SW-1990, Su86.86, BxPC-3, were obtained from
ATCC and grown in RPMI 1640 with 10% fetal bovine serum
and 1% antibiotic/antimycotic (Invitrogen). Capan-1 cells
were also obtained from ATCC and grown in IMDM (Invitro-
gen). Originally, panc-1 (ATCC, CRL-1469) and BxPC-3
(ATCC, CRL-1687) were obtained from primary pancreatic
adenocarcinoma, while SW-1990 (ATCC, CRL-2172) was from
a spleen metastasis and Su86.86 (ATCC, CRL-1837) and
Capan-1 (ATCC, HTB-79) were from liver metastasis.
Side population assay
Adherent cells were harvested with 0.5% trypsin. Aliquots of
106 cells were exposed to 10 μg/ml Hoechst 33342 (Invitro-
gen) in a 37.5 °C incubator for 90 min with constant gentle
agitation. For samples with inhibitor, cells were exposed
first to either 100 μM Verapamil (Sigma) or 10 μM Fumitre-
morgin C (Alexis Biochemicals) for 15 min before adding
Hoechst. After Hoechst incubation, samples were rapidly
cooled on ice for 5–10 min. Samples were centrifuged and
supernatant removed. Pellets were resuspended in 2% FBS/
PBS solution at a concentration of 106 cells/ml. 2 μg/ml of
7-aminoactinomycin D (Invitrogen) was added as a viability
detector. Samples were evaluated for SP on a LSR II cell
analyzer (BD Biosciences).
Extracellular and intracellular marker flow
cytometry
Adherent cells were harvested, and aliquots of 106 cells/ml
were placed in FACS tubes. Cells were washed twice with 2%
FBS/ PBS solution. For extracellular antibody markers, cells
were resuspended in 100 μl of 2%FBS/PBS before incubating
with antibody. Anti-CD20 (FITC-conjugated, 5 μl), anti-
CD133/1 (APC-conjugated, 5 μl), and anti-CD326 (APC-
conjugated, 5 μl) were obtained from Miltenyi Biotec. Anti-
CD24 (FITC-conjugated, 5 μl) was obtained from Invitrogen.
Anti-CD44 (PE-conjugated, 10 μl), and anti-CD184 (PE-
conjugated, 10 μl) were obtained from BD Biosciences.Appropriate isotype controls were also used. Antibodies were
incubated for 30 minutes at 4 °C. Cells were then washed
twice with 2% FBS/ PBS solution, and resuspended in 500 μl of
2% FBS/ PBS prior to reading on a Canto II Flow cytometer (BD
Biosciences). 10 μl of propidium iodinewas added as a viability
stain.
For intracellular markers, Sox-2 and OCT3/4, cells were
aliquoted as above and then fixed with 500 μl of 4%
paraformaldehyde for 30 minutes, and cells permeablized
with 500 μl of 2% Triton-x for 10 minutes, prior to incubating
with antibodies. Sox-2 (PE-conjugated, 10 μl) and OCT ¾
(FITC-conjugated) were used.
Gemcitabine, hypoxia, and radiation exposure
Cells were plated in a sub-confluent fashion. The next day,
they were exposed to normal growth media with various doses
of gemcitabine (NCI veterinary pharmacy), 0.02 μg/ml,
0.01 mg/ml, and 1 mg/ml. Control cells had a media change
with normal growth media only. Cells were allowed to grow
under these conditions for 48 hours (approximately 1 cell
cycle), after which the cells were harvested and analyzed for
SP. Similarly, for hypoxia evaluation, sub-confluent cells were
exposed to 1% oxygen, 5% carbon dioxide, and 94% nitrogen in a
hypoxia chamber at 37.5 °C (Billups-Rothenberg, Inc.) for
48 hours. Control cells were placed in normal atmospheric
conditions in a 37.5 °C incubator. SPwas analyzed as previously
described. For experiments involving radiation exposure, sub-
confluent cells were exposed to 4 Gy and then replaced in the
conventional incubator for 3 days and analyzed for SP.
Combined side population, and cell surface marker
flow cytometry and sorting
Cells were grown in a sub-confluent fashion and harvested
with 0.5% trypsin, washed. Aliquots of 3×106 cells/ml were
made for analysis. Appropriate controls and isotypes were
done to allow for setting of voltages and compensation. The SP
assay was conducted as described above. After completing the
90-minute incubation, cells were placed on ice for 10 min in
the dark. Cells were then centrifuged and washed with cold
2%FBS/PBS. Each FACS tube containing 3×106 cells was then
resuspended in 100 μl of 2% FBS/PBS. Anti-CD44 (PE-
conjugated, 10 μl), anti-CD24 (FITC-conjugated, 5 μl), and
anti-CD326 (APC-conjugated, 5 μl) were added and incubated
for 30 minutes at 4 °C, protected from light. Cells were then
washed twice with 2%FBS/PBS, resuspended in 1 ml. 2 μg/ml
of 7-aminoactinomycin D (Invitrogen) was added as a viability
detector. Compensation beads (BD Biosciences, catalog No.
552843) were prepared using manufacturer instructions and
used to set compensation for each experiment. Samples were
run on the LSR II cell analyzer (BD Biosciences).
Xenotransplantation
Between 200 and 400 million cells were grown and
harvested for sorting and xenotransplantation. Cells were
harvested, counted, and aliquoted into 3×106 cells/ml. For
sorting, 10 ml of this cell concentration was placed in a
125-ml sterile Erlenmeyer flask before incubating with
Hoechst (10 μg/ml) with constant agitation at 37 °C for
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sorted were combined in 50 ml conical tubes and washed
twice with cold 2% FBS/PBS. Cell were resuspended with
100 μl 2%FBS/PBS per 3×106 cells. Antibodies were added:
anti-CD44 (PE-conjugated, 10 μl per 3×106); anti-CD24
(FITC-conjugated, 5 μl per 3×106); and anti-CD326 (APC-
conjugated, 5 μl per 3×106). Cells were incubated for
30 minutes at 4 °C, protected from light. Cells were then
washed twice with 2% FBS/PBS and aliquoted into sorting
tubes at 10×106 cells/ml. Appropriate samples were done
to allow for compensation on a BD FACS Aria II (BD
Biosciences, San Jose, CA). Isotype controls were used to
set gates for each flourchrome. Nine populations were
sorted: whole cell line; SP; non-side population (NSP);
CD44+CD 24+CD326+; CD44-CD24-CD326+; SP/ CD44+CD
24+CD326+; NSP/ CD44+CD 24+CD326+; SP/ CD44-CD24-
CD326+; and NSP/ CD44-CD24-CD326+ (NSP non SP). After
sorting, cells were centrifuged, counted, and resuspended
in 25% matrigel/staining media solution to allow for a
concentration of 100 cells/100 μl. Staining media was made
in RPMI-1640 with 8% DEPC sterile water (Crystalgen), 1%
antibiotic/antimycotic (Invitrogen), 1% 1 M HEPES (Crystal-
gen). 100 μl were used for each injection of aythmic nude
mice (01B74 Athymic NCr-nu/nu) from NCI Frederick Mouse
Repository (Frederick, MD). Several days prior to injection,
mice had electronic IMI-1000 transponders (Bio Medic Data
Systems) implanted in a dorsal-caudal subcutaneous loca-
tion to aid in the blinding of the study. Injections were done
on bilateral front limbs. Injection groups were blinded and
mice were mixed between cages/groups to avoid measure-
ment bias. Subsequent weekly measurements were blinded
until the experiments were terminated at 16 weeks.
Human fresh pancreatic tumor
The “human tumor K” [male, age 48 at diagnosis, pancreatic
tail tumor] cells were generated by mincing fresh human
pancreatic adenocarcinoma tumor into b1 mm pieces and
transplanting them into the subcutaneous tissue of athymic
nude mice. After 1 passage in mice, tumors were harvested
and digested with 1 mg/ml of type IV collagenase (Sigma,
USA) and plated onto tissue culture plates and maintained in
DMEM/F12 with 10% FBS.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.scr.2012.08.001.
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